Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world lenvatinib in locally advanced differentiated thyroid cancer
ChiCTR2100047099Phase 4Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenvatinib in well-differentiated thyroid cancer (WDTC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Started Aug 2021; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ChiCTR2100047099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047099.